Value gained By Sonnet BioTherapeutics Holdings Inc. (SONN) In The Past Week: $4.2000

0
12

Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) finished Thursday with an addition of $0.31 to close at $1.63, an upside of 23.48 percent. An average of 2,681,624 shares of common stock have been traded in the last five days. There was a fall of -$1.5480 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 913,376 shares traded, while the 50-day average volume stands at 384,611.

SONN stock has decreased by -51.26% in the last month. The company shares reached their 1-month lowest point of $1.2300 on 09/21/22. With the stock rallying to its 52-week high on 03/16/22, shares of the company touched a low of $1.23 and a high of $10.22 in 52 weeks. It has reached a new high 3 times so far this year and lost -71.82% or -$4.1534 in price. In spite of this, the price is down -84.05% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Valuation Metrics

Sonnet BioTherapeutics Holdings Inc. (SONN) stock’s beta is 0.59. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 144.19, the price-to-book (PB) ratio at 163.00.

Financial Health

The quick ratio of Sonnet BioTherapeutics Holdings Inc. for the three months ended March 30 was 1.10, and the current ratio was 1.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $0.48 million compared to revenue of $0.48 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Sonnet BioTherapeutics Holdings Inc.’s return on assets was -161.80%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$7.88 million in the quarter, while revenues of -$8.21 million were grew 22.34%. The analyst consensus anticipated Sonnet BioTherapeutics Holdings Inc.’s latest quarter earnings to come in at -$0.12 per share, but it turned out to be -$0.14, a -16.70% surprise. For the quarter, EBITDA amounted to -$7.84 million. Shareholders own equity worth $60.59 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Sonnet BioTherapeutics Holdings Inc. (SONN) price momentum. RSI 9-day as of the close on 22 September was 25.65%, suggesting the stock is oversold, with historical volatility in this time frame at 278.02%.

As of today, SONN’s price is $1.7820 -48.71% or -$1.5480 from its 5-day moving average. SONN is currently trading -50.77% lower than its 20-day SMA and -61.65% lower than its 100-day SMA. However, the stock’s current price level is -59.98% below the SMA50 and -76.72% below the SMA200.

The stochastic %K and %D were 6.34% and 4.23%, respectively, and the average true range (ATR) was 0.5376. With the 14-day stochastic at 13.47% and the average true range at 0.4680, the RSI (14) stands at 25.84%. The stock has reached -0.8439 on the 9-day MACD Oscillator while the 14-day reading was at -1.0445.

Analyst Ratings

The consensus rating for Sonnet BioTherapeutics Holdings Inc. (SONN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SONN, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is SONN’s price target for the next 12 months?

Analysts predict a range of price targets between $22.00 and $22.00, with a median target of $22.00. Taking a look at these predictions, the average price target given by analysts for Sonnet BioTherapeutics Holdings Inc. (SONN) stock is $22.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here